FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy

References

• Lim KE, Kim SR, Kim HK, Kim SR. Symptom clusters and quality of life in subjects with COPD. Respir Care. 2017;62:1203–1211. doi:10.4187/respcare.05374
   PubMed Web of Science ®Google Scholar
• Baloira A, Fuster A, Luis J, et al. Lung deposition and inspiratory flow rate in patients with chronic obstructive pulmonary disease using different inhalation devices: a systematic literature review and expert opinion. Int J COPD. 2021;16:1021–1033. doi:10.2147/COPD.S297980
   Google Scholar
• Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5:691–706. doi:10.1016/S2213-2600(17)30293-X
   PubMed Web of Science ®Google Scholar
• WHO. Mortality and global health estimates. Glob Heal Obs World Heal Organ; 2020. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates. Accessed April 29, 2022.
   Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Arch Bronconeumol. 2021. doi:10.1016/j.arbres.2021.03.005
   Web of Science ®Google Scholar
• López-Campos JL, Gallego EQ, Hernández LC. Status of and strategies for improving adherence to COPD treatment. Int J COPD. 2019;14:1503–1515. doi:10.2147/COPD.S170848
   Google Scholar
• García-río F, Soler-cataluña JJ, Alcazar B, Viejo JL, Miravitlles M. Requirements, strengths and weaknesses of inhaler devices for COPD patients from the expert prescribers’ point of view: results of the EPOCA delphi consensus. COPD. 2017;14:573–580. doi:10.1080/15412555.2017.1365120
   PubMedGoogle Scholar
• Sorino C, Negri S, Spanevello A, Visca D, Scichilone N. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15–18. doi:10.1016/j.ejim.2020.02.023
   PubMed Web of Science ®Google Scholar
• Lavorini F, Corrigan CJ, Barnes PJ, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105:1099–1103. doi:10.1016/j.rmed.2011.03.012
   PubMed Web of Science ®Google Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472. doi:10.2147/tcrm.s160365
   PubMed Web of Science ®Google Scholar
• Lavorini F, Fontana GA, Usmani OS. New inhaler devices - The good, the bad and the ugly. Respiration. 2014;88:3–15. doi:10.1159/000363390
   PubMed Web of Science ®Google Scholar
• Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1:315–320. doi:10.1513/pats.200409-046TA
   PubMedGoogle Scholar
• Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109:785–802. doi:10.1016/j.rmed.2004.04.010
   PubMed Web of Science ®Google Scholar
• Broeders MEAC, Molema J, Hop WCJ, Vermue NA, Folgering HTM. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98:1173–1179. doi:10.1016/j.rmed.2004.04.010
   PubMed Web of Science ®Google Scholar
• Hohmann E, Brand JC, Rossi MJ, Lubowitz JH. Expert opinion is necessary: Delphi panel methodology facilitates a scientific approach to consensus. Arthroscopy. 2018;34:349–351. doi:10.1016/j.arthro.2017.11.022
   PubMed Web of Science ®Google Scholar
• Linstone HA, Turoff M. The Delphi method: techniques and applications. Electronic version. Newark: Information Systems Department College of Computing Sciences New Jersey Institute of Technology; 2002. DOI:10.2307/3150755.
   Google Scholar
• Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32:1008–1015. doi:10.1046/j.1365-2648.2000.t01-1-01567.x
   PubMed Web of Science ®Google Scholar
• de Meyrick J. The Delphi method and health research. Health Educ. 2003;103:7–16. doi:10.1108/09654280310459112
   Google Scholar
• Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC. Arch Bronconeumol. 2012;48:331–337. doi:10.1016/j.arbres.2011.12.009
   PubMed Web of Science ®Google Scholar
• Newman SP, Morén F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981;124:317–320. doi:10.1164/arrd.1981.124.3.317
   PubMed Web of Science ®Google Scholar
• Steed KP, Towse LJ, Freund B, Newman SP. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose respimat nebuliser.1 the respimat device was formerly known as the Bineb.1. Eur J Pharm Sci. 1997;5:55–61. doi:10.1016/S0928-0987(96)00016-4
   Web of Science ®Google Scholar
• Vidgren MT, Paronen TP, Kärkkäinen A, Karjalainen P. Effect of extension devices on the drug deposition from inhalation aerosols. Int J Pharm. 1987;39:107–112. doi:10.1016/0378-5173(87)90204-3
   Web of Science ®Google Scholar
• Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122:510–516. doi:10.1378/chest.122.2.510
   PubMed Web of Science ®Google Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137–148. doi:10.1089/jamp.2009.0772
   PubMed Web of Science ®Google Scholar
• Ashworth HL, Wilson CG, Sims EE, Wotton PK, Hardy JG. Delivery of propellant soluble drug from a metered dose inhaler. Thorax. 1991;46:245–247. doi:10.1136/thx.46.4.245
   PubMed Web of Science ®Google Scholar
• Gillen M, Forte P, Svensson JO, et al. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort(®) (budesonide/formoterol) pressurized metered dose inhaler. Pulm Pharmacol Ther. 2018;52:7–17. doi:10.1016/j.pupt.2018.08.001
   PubMed Web of Science ®Google Scholar
• Rahmatalla MF, Zuberbuhler PC, Lange CF, Finlay WH. In vitro effect of a holding chamber on the mouth-throat deposition of QVAR (hydrofluoroalkane-beclomethasone dipropionate). J Aerosol Med. 2002;15:379–385. doi:10.1089/08942680260473452
   PubMedGoogle Scholar
• Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med. 2001;14:197–208. doi:10.1089/08942680152484126
   PubMedGoogle Scholar
• Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46:712–716. doi:10.1136/thx.46.10.712
   PubMed Web of Science ®Google Scholar
• Newman SP, Pitcairn GR, Adkin DA, Vidgren MT, Silvasti M. Comparison of beclomethasone dipropionate delivery by easyhaler dry powder inhaler and pMDI plus large volume spacer. J Aerosol Med. 2001;14:217–225. doi:10.1089/08942680152484144
   PubMedGoogle Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–1504. doi:10.1164/rccm.200410-1414OC
   PubMed Web of Science ®Google Scholar
• Shaw JG, Vaughan A, Dent AG, et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2014;6:1532–1547. doi:10.3978/j.issn.2072-1439.2014.11.33
   PubMed Web of Science ®Google Scholar
• Hira D, Koide H, Nakamura S, et al. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. PLoS One. 2018;13:e0193082. doi:10.1371/journal.pone.0193082
   PubMed Web of Science ®Google Scholar
• Azouz W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J. 2012;21:208–213. doi:10.4104/pcrj.2012.00010
   PubMedGoogle Scholar
• Clark A. Peak inspiratory conditions in healthy volunteers implications for in vitro testing. J Aerosol Med Pulm Drug Deliv. 1993;6:99–110.
   Google Scholar
• Al-Showair RAM, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101:2395–2401. doi:10.1016/j.rmed.2007.06.008
   PubMed Web of Science ®Google Scholar
• Verbanck S, Kalsi HS, Biddiscombe MF, et al. Inspiratory and expiratory aerosol deposition in the upper airway. Inhal Toxicol. 2011;23:104–111. doi:10.3109/08958378.2010.547535
   PubMed Web of Science ®Google Scholar
• Iwanaga T, Kozuka T, Nakanishi J, et al. Aerosol deposition of inhaled corticosteroids/long-acting β2-agonists in the peripheral airways of patients with asthma using functional respiratory imaging, a novel imaging technology. Pulm Ther. 2017;3:219–231. doi:10.1007/s41030-017-0036-4
   Google Scholar
• Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with respimat® soft mistTM inhaler than HFA-MDI in COPD patients with poor technique. Int J COPD. 2008;3:763–770. doi:10.2147/COPD.S3930
   Google Scholar
• Fernández Tena A, Casan Clarà P. Depósito pulmonar de partículas inhaladas. Arch Bronconeumol. 2012;48:240–246. doi:10.1016/j.arbres.2012.02.003
   PubMed Web of Science ®Google Scholar